A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment

Ibrutinib (IBR) covalently binds to the active site of Bruton’s tyrosine kinase (BTK) and is used for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). Approximately 5-10% of CLL is complicated by autoimmune cytopenia (AIC), such as autoimmune hemolytic anemia (AIHA). Several...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Takaharu, Miyakoshi, Shukuko, Nanba, Ayako, Uchiyama, Takayoshi, Kawamoto, Keisuke, Aoki, Sadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JSLRT 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408179/
https://www.ncbi.nlm.nih.gov/pubmed/30012921
http://dx.doi.org/10.3960/jslrt.18012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408179/
https://www.ncbi.nlm.nih.gov/pubmed/30012921
http://dx.doi.org/10.3960/jslrt.18012

Ejemplares similares